Freestone Capital Holdings’s AstraZeneca AZN Stock Holding History

Freestone Capital Holdings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	1,615 +210	+15%	+$39.5K	0.01%	481
2026 Q1	$277K	Sell	1,405 -38	-3%	-$7.33K	0.01%	456
2025 Q4	$265K	Buy	1,443 +86	+6%	+$15.1K	0.01%	452
2025 Q3	$208K	Buy	+1,357	New	+$205K	0.01%	502
2022 Q2	–	Sell	-1,563	Closed	-$207K	–	440
2022 Q1	$207K	Buy	+1,563	New	+$187K	0.01%	538
2021 Q1	–	Sell	-1,286	Closed	-$129K	–	449
2020 Q4	$129K	Sell	1,286 -271	-17%	-$28.7K	0.01%	395
2020 Q3	$171K	Sell	1,557 -17,216	-92%	-$1.91M	0.01%	345
2020 Q2	$1.99K	Sell	18,773 -1,167	-6%	-$121K	0.02%	160
2020 Q1	$1.78K	Buy	19,940 +1,101	+6%	+$104K	0.04%	145
2019 Q4	$1.88K	Buy	18,839 +573	+3%	+$53.9K	0.04%	186
2019 Q3	$1.63K	Buy	18,266 +2,131	+13%	+$185K	0.04%	197
2019 Q2	$1.33K	Buy	16,135 +1,922	+14%	+$151K	0.03%	206
2019 Q1	$1.15M	Buy	14,213 +6,144	+76%	+$484K	0.07%	203
2018 Q4	$613K	Buy	8,069 +3,808	+89%	+$297K	0.04%	262
2018 Q3	$337K	Buy	+4,261	New	+$322K	﹤0.01%	312
2014 Q3	–	Sell	-40,551	Closed	-$3.01M	–	135
2014 Q2	$3.01M	Buy	+40,551	New	+$2.93M	0.47%	40

Other funds holding AZN

EPGL

Evelyn Partners Group Ltd London $46.9B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Freestone Capital Holdings's AZN Position: Q2 2026 in Review

Freestone Capital Holdings increased its AstraZeneca (AZN) stake by 15% in Q2 2026, buying an estimated $39.5K and bringing the position to 1,615 shares worth $306K. The position accounts for 0.01% of the portfolio, ranked #481.

Freestone Capital Holdings first reported a position in AZN in Q2 2014 and has held it in 16 quarters since. The position peaked at $3.01M in Q2 2014. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Freestone Capital Holdings held 1,615 shares of AstraZeneca worth $306K as of Q2 2026.
Freestone Capital Holdings bought 210 AstraZeneca shares in Q2 2026, an estimated $39.5K.
AstraZeneca made up 0.01% of Freestone Capital Holdings's portfolio in Q2 2026, its #481 holding.
Freestone Capital Holdings first reported a position in AstraZeneca in Q2 2014 and has held it in 16 quarters since.
Freestone Capital Holdings's AstraZeneca position peaked at $3.01M in Q2 2014.
906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.